Some aspects of anti-inflammatory therapy of osteoarthritis
https://doi.org/10.21518/ms2023-251
Abstract
In the article, the authors discuss the therapy of OA as one of the common diseases of the musculoskeletal system, which leads to disability of people of working age. Focusing on modern concepts of pathogenesis, the article draws attention to pain and the mechanisms of its formation in OA. The recommendations of the world’s leading communities (EULAR, ARC OARSI) and the conclusions of the consensus resolution of experts of the Russian Federation on the diagnosis and treatment of osteoarthritis 2022 are also given. The article draws attention to some aspects of pain therapy. The data of studies and meta-analyses demonstrating the effectiveness of NSAIDs in pain associated with OA are presented. Among the variety of NSAIDs, the article provides data on the efficacy and safety of nimesulide, as well as its additional properties such as inhibition of cancer cell proliferation, neuroprotective and gastroprotective effects. The conclusions of the consensus meetings of 2005, the purpose of which was to provide a continuous and up-to-date assessment of the clinical profile and safety profile of nimesulide, and 2014, the purpose of which was to familiarize with the current state of pathophysiology and treatment of acute pain with a special focus on nimesulide, are presented. The article also provides data on the safety and efficacy of nimesulide in the treatment of OA in comparison with drugs such as diclofenac, naproxen and ibuprofen. One of the little-studied aspects of pain therapy is the patient’s preference. The article presents data from studies of the effectiveness of various forms of NSAIDs and patient preferences in therapy. The authors of the article conclude that the most acceptable from the point of view of efficacy, safety, the rate of onset of the effect, as well as the preferences of patients is nimesulide in the form of granules for the preparation of a solution.
About the Authors
Yu. S. Filatova
Yaroslavl State Medical University; “Center for diagnostics and prevention plus” LLC
Russian Federation
Russian Federation
Yulia S. Filatova - Cand. Sci. (Med.), Associate Professor of the Department of Therapy named after E.N. Dormidontov of the Institute of Continuing Professional Education, Yaroslavl SMU; Rheumatologist, “Center for diagnostics and prevention plus” LLC;
5, Revolutsionnaya St., Yaroslavl, 150000; 33, Lenin Ave., Yaroslavl, 150003
I. N. Solovyov
Yaroslavl State Medical University; “Center for diagnostics and prevention plus” LLC
Russian Federation
Russian Federation
Igor N. Solovyov - Cand. Sci. (Med.), Associate Professor of the Department of Traumatology and Orthopedics, Yaroslavl SMU; Orthopedic Traumatologist, “Center for diagnostics and prevention plus” LLC.
5, Revolutsionnaya St., Yaroslavl, 150000; 33, Lenin Ave., Yaroslavl, 150003
References
1. Hunter D.J., Bierma- Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182): 1745–1759. https://doi.org/10.1016/S0140-6736(19)30417-9.
2. Quicke J.G., Conaghan P.G., Corp N., Peat G. Osteoarthritis year in review 2021: epidemiology & therapy. Osteoarthritis Cartilage. 2022;30(2):196–206. https://doi.org/10.1016/j.joca.2021.10.003.
3. Long H., Liu Q., Yin H., Wang K., Diao N., Zhang Y. et al. Prevalence Trends of Site- Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74(7):1172–1183. https://doi.org/10.1002/art.42089.
4. Allen K.D., Thoma L.M., Golightly Y.M. Epidemiology of osteoarthritis. Osteoarthritis Cartilage. 2022;30(2):184–195. https://doi.org/10.1016/j.joca.2021.04.020.
5. Molnar V., Matišić V., Kodvanj I., Bjelica R., Jeleč Ž., Hudetz D. et. Al Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. Int J Mol Sci. 2021;22(17):9208. https://doi.org/10.3390/ijms22179208.
6. Fioravanti A., Tenti S., Cheleschi S. Editorial: Year 2020: New Trends in Pharmacological Treatments for Osteoarthritis. Front Pharmacol. 2022;13:892934. https://doi.org/10.3389/fphar.2022.892934.
7. Abramoff B., Caldera F.E. Osteoarthritis: Pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104(2):293–311. https://doi.org/10.1016/j.mcna.2019.10.007.
8. Fioravanti A., Tenti S., McAllister M., Chemaly M., Eakin A., McLaughlin J. et al. Exploring the Involvement of NLRP3 and IL-1β in Osteoarthritis of the Hand: Results from a Pilot Study. Mediators Inflamm. 2019;2019:2363460. https://doi.org/10.1155/2019/2363460.
9. Salaffi F., Ciapetti A., Carotti M. The sources of pain in osteoarthritis: A pathophysiological review. Reumatismo. 2014;66(1):57–71. https://doi.org/10.4081/reumatismo.2014.766.
10. Zhang Y., Nevitt M., Niu J., Lewis C., Torner J., Guermazi A. et al. Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis Rheum. 2011;63(3):691–699. https://doi.org/10.1002/art.30148.
11. Morgan M., Thai J., Nazemian V., Song R., Ivanusic J.J. Changes to the activity and sensitivity of nerves innervating subchondral bone contribute to pain in late-stage osteoarthritis. Pain. 2022;163(2):390–402. https://doi.org/10.1097/j.pain.0000000000002355.
12. Zhu S., Zhu J., Zhen G., Hu Y., An S., Li Y. et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Investig. 2019;129(3):1076–1093. https://doi.org/10.1172/JCI121561.
13. Belluzzi E., Stocco E., Pozzuoli A., Granzotto M., Porzionato A., Vettor R. et al. Contribution of infrapatellar fat pad and synovial membrane to knee osteoarthritis pain. Biomed Res Int. 2019;2019:6390182. https://doi.org/10.1155/2019/6390182.
14. Belluzzi E., Macchi V., Fontanella C.G., Carniel E.L., Olivotto E., Filardo G. et al. Infrapatellar fat pad gene expression and protein production in patients with and without osteoarthritis. Int J Mol Sci. 2020;21(17):6016. https://doi.org/10.3390/ijms21176016.
15. Yu H., Huang T., Lu W.W., Tong L., Chen D. Osteoarthritis Pain. Int J Mol Sci. 2022;23(9):4642. https://doi.org/10.3390/ijms23094642.
16. Yao Q., Wu X., Tao C., Gong W., Chen M., Qu M. et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):56. https://doi.org/10.1038/s41392-023-01330-w.
17. Katz J.N., Arant K.R., Loeser R.F. Diagnosis and treatment of hip and knee osteoarthritis: A review. JAMA. 2021;325(6):568–578. https://doi.org/10.1001/jama.2020.22171.
18. Richard M.J., Driban J.B., McAlindon T.E. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023;31(4):458–466. https://doi.org/10.1016/j.joca.2022.11.005.
19. Oo W.M., Yu S.P., Daniel M.S., Hunter D.J. Disease- modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs. 2018;23(4):331–347. https://doi.org/10.1080/14728214.2018.1547706.
20. Filatova Yu.S., Ilyin M.V., Soloviev I.N. Osteoarthritis: modern possibilities of therapy. Ambulatornaya Khirurgiya. 2022;(1):60–67. (In Russ.) https://doi.org/10.21518/1995-1477-2022-19-1-60-67.
21. Kolasinski S.L., Neogi T., Hochberg M.C., Oatis C., Guyatt G., Block J. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149–162. https://doi.org/10.1002/acr.24131.
22. Kloppenburg M., Kroon F.P., Blanco F.J., Doherty M., Dziedzic K.S., Greibrokk E. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16–24. https://doi.org/10.1136/annrheumdis-2018-213826.
23. Bannuru R.R., Osani M.C., Vaysbrot E.E., Arden N.K., Bennell K. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589. https://doi.org/10.1016/j.joca.2019.06.011.
24. Lila A.M., Mazurov V.I., Martynov A.I., Zagorodny N.V., Alekseeva L.I., Chichasova N.V. et al. Resolution of the consensus of the Russian Federation experts on the diagnosis and treatment of osteoarthritis, 2022. Sovremennaya Revmatologiya. 2022;(6):106–116. (In Russ.) https://doi.org/10.14412/1996-7012-2022-6-106-116.
25. da Costa B.R., Reichenbach S., Keller N., Nartey L., Wandel S., Jüni P., Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21–e33. https://doi.org/10.1016/S0140-6736(17)31744-0.
26. Osani M.C., Vaysbrot E.E., Zhou M., McAlindon T.E., Bannuru R.R. Duration of Symptom Relief and Early Trajectory of Adverse Events for Oral Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis: A Systematic Review and Meta- Analysis. Arthritis Care Res (Hoboken). 2020;72(5):641–651. https://doi.org/10.1002/acr.23884.
27. Ton J., Perry D., Thomas B., Allan G.M., Lindblad A.J., McCormack J. et al. PEER umbrella systematic review of systematic reviews: Management of osteoarthritis in primary care. Can Fam Physician. 2020;66(3):e89–e98. Available at: https://pubmed.ncbi.nlm.nih.gov/32165479.
28. Wongrakpanich S., Wongrakpanich A., Melhado K., Rangaswami J. A Comprehen sive Review of Non- Steroidal Anti- Inflammatory Drug Use in The Elderly. Aging Dis. 2018;9(1):143–150. https://doi.org/10.14336/AD.2017.0306.
29. Sostres C., Gargallo C.J., Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;(Suppl. 3):S3. https://doi.org/10.1186/ar4175.
30. Honvo G., Leclercq V., Geerinck A., Thomas T., Veronese N., Charles A. et al. Safety of Topical Non-steroidal Anti- Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta- Analysis. Drugs Aging. 2019;36(1):45–64. https://doi.org/10.1007/s40266-019-00661-0.
31. Nasonov E.L. Efficacy and tolerability of a nonsteroidal anti-inflammatory drug. Nimesulide: new data. RMJ. 2001;(15):636–638. (In Russ.) Availablt at: https://www.rmj.ru/articles/revmatologiya/Effektivnosty_i_perenosimosty_nesteroidnogo_protivovospalitelynogo_preparata_Nimesulid_novye_dannye/#.
32. Camu F., Shi L., Vanlersberghe C. The role of COX-2 inhibitors in pain modulation. Drugs. 2003;63(1):1–7. https://doi.org/10.2165/00003495200363001-00002.
33. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.A. Nonsteroid drug selectivities for cyclo- oxygenase-1 rather than cyclo- oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96(13):7563–7568. https://doi.org/10.1073/pnas.96.13.7563.
34. Magni E. The effect of nimesulide on prostanoid formation. Drugs. 1993;46(1):10–14. https://doi.org/10.2165/00003495-199300461-00004.
35. Davis R., Brogden R.N. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1994;48(3):431–454. https://doi.org/10.2165/00003495-199300461-00004.
36. Shaik M.S., Chatterjee A., Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor- gamma. Clin Cancer Res. 2004;10(4):1521–1529. https://doi.org/10.1158/1078-0432.ccr-0902-03.
37. Liang M., Yang H., Fu J. Nimesulide inhibits IFNgamma- induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett. 2009;276(1): 47–52. https://doi.org/10.1016/j.canlet.2008.10.028.
38. Afzal M., Bhardwaj D.P., Khan R., Kazmi I., Saleem S., Al- Abbasi F.A., Anwar F. Antineoplastic influence of nimesulide in chemically induced hepatocellular carcinoma by inhibition of DNA synthesis. Inflammopharmacology. 2019;27(1):89–98. https://doi.org/10.1007/s10787-018-0481-1.
39. Candelario- Jalil E. Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences. Pharmacol Res. 2008;57(4):266–273. https://doi.org/10.1016/j.phrs.2008.03.003
40. Zanjani T.M., Sabetkasaei M., Karimian B., Labibi F., Farokhi B., Mossafa N. The attenuation of pain behaviour and serum interleukin-6 concentration by nimesulide in a rat model of neuropathic pain. Scand J Pain. 2010;1(4):229–234. https://doi.org/10.1016/j.sjpain.2010.08.003.
41. Zolotovskaia I. A., Davydkin I. L. Cognitive- cytokine effect of nonsteroidal antiinfl amatory drugs in the therapy of elderly patients with osteoarthritis. Advances in Gerontology. 2017;(3):381–389. (In Russ.) Available at: http://www.gersociety.ru/netcat_files/userfiles/10/AG_2017-30-03.pdf.
42. Vunnam N., Young M.C., Liao E.E., Lo C.H., Huber E., Been M. et. al. Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAILinduced apoptosis by promoting DR5 clustering. Cancer Biol Ther. 2023;24(1):2176692. https://doi.org/10.1080/15384047.2023.2176692.
43. Catarro M., Serrano J.L., Ramos S.S., Silvestre S., Almeida P. Nimesulide Analogues: From Anti- Inflammatory to Antitumor Agents. Bioorg Chem. 2019;88:102966. https://doi.org/10.1016/j.bioorg.2019.102966.
44. Caiazzo E., Ialenti A., Cicala C. The Relatively Selective Cyclooxygenase-2 Inhibitor Nimesulide: What’s Going on? Eur J Pharmacol. 2019;848:105–111. https://doi.org/10.1016/j.ejphar.2019.01.044.
45. Uram Ł., Filipowicz- Rachwał A., Misiorek M., Winiarz A., Wałajtys- Rode E., Wołowiec S. Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted With Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells. Biomolecules. 2019;9(9):437. https://doi.org/10.3390/biom9090437.
46. Suleyman H., Cadirci E., Albayrak A., Halici Z. Nimesulide is a Selective COX-2 Inhibitory, Atypical Non- Steroidal Anti- Inflammatory Drug. Curr Med Chem. 2008;15(3):278–283. https://doi.org/10.2174/092986708783497247.
47. Sengel- Turk C.T., Hascicek C., Bakar F., Simsek E. Comparative Evaluation of Nimesulide- Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells. AAPS PharmSciTech. 2017;18(2):393–403. https://doi.org/10.1208/s12249-016-0514-2.
48. Nam K.T., Hahm K.B., Oh S.Y., Yeo M., Han S.U., Ahn B. et al. The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter Pylori- Associated Gastric Cancer Development in a Mouse Model. Clin Cancer Res. 2004;10(23):8105–8113. https://doi.org/10.1158/1078-0432.CCR-04-0896.
49. Chu M., Wang T., Sun A., Chen Y. Nimesulide Inhibits Proliferation and Induces Apoptosis of Pancreatic Cancer Cells by Enhancing Expression of PTEN. Exp Ther Med. 2018;16(1):370–376. https://doi.org/10.3892/etm.2018.6191.
50. Ferreira R.G., Narvaez L.E.M., Espíndola K.M.M., Rosario A.C.R.S., Lima W.G.N., Monteiro M.C. Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer? Front Oncol. 2021;11:594917. https://doi.org/10.3389/fonc.2021.594917.
51. Mattia C., Ciarcia S., Muhindo A., Coluzzi F. Nimesulide: 25 years later. Minerva Med. 2010;101(4):285–293. Available at: https://pubmed.ncbi.nlm.nih.gov/21030939.
52. Rainsford K.D. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006;22(6):1161–1170. https://doi.org/10.1185/030079906X104849.
53. Kress H.G., Baltov A., Basiński A., Berghea F., Castellsague J., Codreanu C. et. аl. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin. 2016;32(1):23–36. https://doi.org/10.1185/03007995.2015.1100986.
54. Fossaluzza V., Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double- blind trial versus naproxen. J Int Med Res. 1989;17(3):295–303. https://doi.org/10.1177/030006058901700313.
55. Fioravanti A., Storri L., Di Martino S., Bisogno S., Oldani V., Scotti A., Marcolongo R. A randomized, double- blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis. Clin Ther. 2002;24(4):504–519. https://doi.org/10.1016/s0149-2918(02)85127-x.
56. Kriegel W., Korff K.J., Ehrlich J.C., Lehnhardt K., Macciocchi A., Moresino C., Pawlowski C. Double- blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract. 2001;55(8):510–514. Available at: https://pubmed.ncbi.nlm.nih.gov/11695069.
57. Alexeeva L.I., Karateev A.E., Popkova T.V., Novikova D.S., Sharapova E.N., Markelova E.P., Nasonov E.L. Efficacy and safety of nimesulide long term administration in patients with osteoarthritis: results of 12-months open controlled study DINAMO (Long Term Administration of Nimesulide in Osteoarthritis Multifactor Assessment). Rheumatology Science and Practice. 2009;(4): 64–72. (In Russ.) Available at: https://elibrary.ru/item.asp?id=20343992.
58. Wober W., Rahlfs V.W., Büchl N., Grässle A., Macciocchi A. Comparative efficacy and safety of the non-steroidal anti-inflammatory drugs nimesulide and diclofenac in patients with acute subdeltoid bursitis and bicipital tendinitis. Int J Clin Pract. 1998;52(3):169–175. Available at: https://pubmed.ncbi.nlm.nih.gov/9684433/.
59. Huskisson E.C., Macciocchi A., Rahlfs V., Bernstein R.M., Bremner A.D., Doyle D.V. et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: An active controlled equivalence study. Curr Ther Res. 1999;60:253–265. https://doi.org/10.1016/S0011-393X(99)80002-2.
60. Pohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX–2–selective anti–inflammatory drug nimesulide: results of a randomized, double–blind comparative trial versus ibuprofen. Spine. 2000;25(12):1579–1585. https://doi.org/10.1097/00007632-200006150-00019.
61. Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract. 2004;(144):27–32. https://doi.org/10.1111/j.1742-1241.2004.027_e.x.
62. Conforti A., Leone R., Moretti U., Mozzo F., Velo G. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081–1090. https://doi.org/10.2165/00002018-200124140-00006.
63. Danilov A.B. Algorithm for choosing the dosage form of a nonsteroidal anti-inflammatory drug. Lechaschi Vrach. 2010;(7):74. (In Russ.) Available at: https://www.lvrach.ru/2010/07/15081982.
64. Combe B., Vélicitat P., Garzón N., Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001;50(1):10–16. https://doi.org/10.1007/PL00022374.
65. Neighbor M.L., Puntillo K.A. Intramuscular ketorolac vs oral ibuprofen in emergency department patients with acute pain. Acad Emerg Med. 1998;5(2):92–93. https://doi.org/10.1007/PL00022374.
66. Shrestha M., Morgan D.L., Moreden J.M., Singh R., Nelson M., Hayes J.E. Randomized double- blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995;26(6):682–686. https://doi.org/10.1016/s0196-0644(95)70037-4.
67. Tramèr M.R., Williams J.E., Carroll D., Wiffen P.J., Moore R.A., McQuay H.J. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998;42(1):71–79. https://doi.org/10.1111/j.1399-6576.1998.tb05083.x.
68. Atkinson T.J., Fudin J. Nonsteroidal Antiinflammatory Drugs for Acute and Chronic Pain. Phys Med Rehabil Clin N Am. 2020;31(2):219–231. https://doi.org/10.1016/j.pmr.2020.01.002.10.
69. Gupta A., Bah M. NSAIDs in the Treatment of Postoperative Pain. Curr Pain Headache Rep. 2016;20(11):62. https://doi.org/10.1007/s11916-016-0591-7.
70. Shatsky М. Evidence for the use of intramuscular injections in outpatient practice. Fam Physician. 2009;79(4):297–300. Available at: https://pubmed.ncbi.nlm.nih.gov/19235496.
71. Dougados M., Listrat V., Duchesne L., Amor B. Comparative efficacy of ketoprofen related to the route of administration (intramuscular or per os). A double- blind study versus placebo in rheumatoid arthritis. Rev Rhum Mal Osteoartic. 1992;59(11):769–773. Available at: https://pubmed.ncbi.nlm.nih.gov/1306600.
72. Kim C., Armstrong M.J., Berta W.B., Gagliardi A.R. How to identify, incorporate and report patient preferences in clinical guidelines: A scoping review. Health Expect. 2020;23(5):1028–1036. https://doi.org/10.1111/hex.13099.
73. Dmitrieva E.V., Egorova S.N. Hard peroral medical forms: the study of consumer preferences of patients (by the example of antihypertensive preparations). Medical Almanac. 2010;(4):67–70. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=15321050.
Review
For citations:
Filatova YS, Solovyov IN. Some aspects of anti-inflammatory therapy of osteoarthritis. Meditsinskiy sovet = Medical Council. 2023;(13):157-164. (In Russ.) https://doi.org/10.21518/ms2023-251
Views:
574
Email this article 